| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 25,399.0 | 23,993.0 |
| Gross profit | 17,302.0 | 16,690.0 |
| Profit before tax | 34.0 | 7,493.0 |
| Net income | 210.0 | 5,152.0 |
| EPS (diluted, $ a share) | $0.09 | $2.12 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | -95.9% |
|---|---|
| Revenue, year on year | +5.9% |
| Gross margin | 68.1% |
10-Q filed with the SEC, NYSE: JNJ. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Johnson & Johnson: key numbers
- Share price
- $282.55Close, Nov 16
- Market cap
- $680B
- Shares outstanding
- 2.41BLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Johnson & Johnson
All →Johnson & Johnson Financial Results
Johnson & Johnson reported Q3 2026 sales growth of 5.9% to $25.4 billion, driven by strong performance in its Innovative Medicine and MedTech segments. The company raised its full-year 2026 guidance for both sales and adjusted EPS, despite a GAAP earnings impact from a one-time special charge related to talc litigation and recent M&A activity.
- Term
- Q3 2026
“Johnson & Johnson’s strong third-quarter performance and increased sequential growth reflect the accelerating momentum of our focused portfolio.”
Joaquin Duato, Chairman and Chief Executive Officer
“This progress, together with strategic investments in high-growth areas, gives us clearer line of sight to double-digit growth by the end of the decade.”
Joaquin Duato, Chairman and Chief Executive Officer